In the journal European Neuropsychopharmacology, a team of researchers have suggested that the combination of psychedelics and psychotherapy may be the most effective for posttraumatic stress disorder (PTSD).
The study centered on two psychedelic interventions: MDMA (ecstasy) and psilocybin (psychedelic mushrooms).
The findings were published in a post-COVID world.
“A sharp increase in the prevalence of neuropsychiatric disorders, including major depression, anxiety, substance use disorders and posttraumatic stress disorder (PTSD) has occurred due to the traumatic nature of the persisting COVID-19 global pandemic,’ the study’s authors explained in their findings.
“This review summarizes the neurobiological and neuroanatomical underpinnings of PTSD and discusses the conventional and emerging psychotherapies, pharmacological and combined psychopharmacological therapies, including the use of psychedelic-assisted psychotherapies and neuromodulatory interventions, for the improved treatment of PTSD and the potential for their wider applications in other neuropsychiatric disorders resulting from traumatic exposure.”
